Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | plasmepsin IV | 0.0121 | 0 | 0.5 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0121 | 0 | 0.5 |
Onchocerca volvulus | 0.0121 | 0 | 0.5 | |
Leishmania major | cysteine peptidase C (CPC),CPC cysteine peptidase, Clan CA, family C1, Cathepsin B-like | 0.0317 | 0.0676 | 0.5 |
Plasmodium falciparum | plasmepsin III | 0.0121 | 0 | 0.5 |
Loa Loa (eye worm) | cathepsin B | 0.0317 | 0.0676 | 0.2333 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0961 | 0.2898 | 0.2898 |
Plasmodium vivax | aspartyl protease, putative | 0.0121 | 0 | 0.5 |
Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.0961 | 0.2898 | 1 |
Plasmodium falciparum | plasmepsin VIII, putative | 0.0121 | 0 | 0.5 |
Brugia malayi | cathepsin B-like cysteine proteinase | 0.0961 | 0.2898 | 1 |
Schistosoma mansoni | nuclear hormone receptor superfamily protein-related | 0.0784 | 0.2287 | 0.2287 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0961 | 0.2898 | 0.2898 |
Echinococcus granulosus | cathepsin b | 0.0961 | 0.2898 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0961 | 0.2898 | 1 |
Echinococcus granulosus | cathepsin b | 0.0961 | 0.2898 | 1 |
Echinococcus multilocularis | cathepsin b | 0.0961 | 0.2898 | 1 |
Trichomonas vaginalis | Clan CA, family C1, cathepsin B-like cysteine peptidase | 0.0317 | 0.0676 | 1 |
Plasmodium vivax | plasmepsin V, putative | 0.0121 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin V | 0.0121 | 0 | 0.5 |
Onchocerca volvulus | 0.0121 | 0 | 0.5 | |
Plasmodium vivax | aspartyl protease, putative | 0.0121 | 0 | 0.5 |
Toxoplasma gondii | cathepsin B | 0.0317 | 0.0676 | 1 |
Giardia lamblia | Cathepsin B precursor | 0.0317 | 0.0676 | 0.5 |
Giardia lamblia | Cathepsin B precursor | 0.0317 | 0.0676 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0961 | 0.2898 | 0.2898 |
Plasmodium falciparum | plasmepsin VII | 0.0121 | 0 | 0.5 |
Giardia lamblia | Cathepsin B precursor | 0.0317 | 0.0676 | 0.5 |
Trypanosoma brucei | cysteine peptidase C (CPC) | 0.0317 | 0.0676 | 0.5 |
Plasmodium falciparum | plasmepsin X | 0.0121 | 0 | 0.5 |
Echinococcus multilocularis | cathepsin b | 0.0961 | 0.2898 | 1 |
Plasmodium falciparum | plasmepsin IX | 0.0121 | 0 | 0.5 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0121 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin II | 0.0121 | 0 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0317 | 0.0676 | 0.0676 |
Plasmodium falciparum | plasmepsin VI | 0.0121 | 0 | 0.5 |
Plasmodium vivax | plasmepsin IV, putative | 0.0121 | 0 | 0.5 |
Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.0961 | 0.2898 | 0.2898 |
Plasmodium vivax | aspartyl protease, putative | 0.0121 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin I | 0.0121 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (binding) | = 87 % | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 100 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 87 % | Inhibition of COX1 in human whole blood assessed as effect on A23187-induced thromboxane B2 production at 100 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 93 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 10 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 93 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 10 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 100 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 1 uM relative to control | ChEMBL. | 17994684 |
Inhibition (binding) | = 100 % | Inhibition of COX2 in human whole blood assessed as effect on LPS-induced thromboxane B2 production at 1 uM relative to control | ChEMBL. | 17994684 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.